Capturing demand related to COVID-19
First written in FY2022-Q2. 5 of 9 entries say "Softened", first in FY2023-Q1. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024SoftenedAnnual report
「Although there was a decline in PCR testing volumes in the LSIM business and a contraction of exceptional demand for ultra-low-temperature freezers used to store mRNA vaccines in the Biomedica business, among other factors」
Exceptional demand for PCR testing and ultra-low-temperature freezers used to store vaccines contracted further even on a full-year basis, and the capture of COVID-19-related demand weakened further. - FY2024-Q3SoftenedAnnual report
「Despite favorable foreign exchange effects, Diabetes Management, Healthcare Solutions, and Diagnostics and Life Science each reported lower revenue due to the ongoing contraction of the market, mainly in Europe, and the impact of the end of a sales collaboration in the United States in the blood glucose monitoring system (BGM) business, the decline in PCR testing volumes in the LSIM business, and the contraction of exceptional demand for ultra-low-temperature freezers used to store mRNA vaccines in the Biomedica business, among other factors.」
Demand for PCR testing and exceptional demand for ultra-low-temperature freezers used to store mRNA vaccines contracted further, and the shift from capturing COVID-19-related demand to general demand is progressing. - FY2024-Q2SoftenedAnnual report
「The decline in PCR testing accompanying the reclassification of COVID-19 in clinical testing from the equivalent of Category 2 to Category 5」
COVID-19-related demand for PCR testing contracted further, and the disclosures have shifted from describing the capture of related demand to describing the impact of declining demand. - FY2024-Q1SoftenedAnnual report
「In the Biomedica business, sales in the research and medical support equipment field declined year on year as exceptional demand for ultra-low-temperature freezers used to store mRNA vaccines contracted. Excluding exceptional demand, however, sales generated by general demand increased due to favorable effects from price revisions and foreign exchange movements.」
Exceptional COVID-19-related demand for ultra-low-temperature freezers contracted further, and the center of demand is shifting to general demand. - FY2023-Q3RestatedAnnual report
「In the diagnostics business, we also began selling combination test kits for COVID-19 and influenza. Sales of COVID-19 antigen test kits increased revenue, but revenue declined year on year due to lower sales of COVID-19-related reagents for overseas markets, which were used mainly for patients at risk of severe disease, as the less severe Omicron variant became predominant.」
While capturing related demand through the launch of combination test kits and increased revenue from antigen test kits, revenue from related reagents for overseas markets declined due to the impact of the Omicron variant. - FY2023-Q2RestatedAnnual report
「Sales of COVID-19 antigen test kits increased, but revenue from related reagents for overseas markets, which were used mainly for patients at risk of severe disease, declined as the Omicron variant, which has a lower rate of severe disease, became predominant.」
While capturing some related demand, including increased sales of antigen test kits, revenue from related reagents for overseas markets declined as the Omicron variant became predominant. Exceptional large-scale demand for ultra-low-temperature freezers subsided, and the shift in the demand mix continued. - FY2023-Q1SoftenedAnnual report
「In the Biomedica business, exceptional demand for ultra-low-temperature freezers used to store mRNA vaccines subsided, while general demand began to recover.」
Exceptional COVID-19-related demand for ultra-low-temperature freezers subsided, and the center of demand shifted to a recovery in general demand. - FY2022-Q3AdvancedAnnual report
「In the LSIM business, the number of specimens for general testing remained on a recovery trend in the second quarter of the current fiscal year, following the second quarter of the previous fiscal year. In addition, revenue increased substantially due to expanded contract PCR testing and expanded sales of COVID-19-related reagents.」
For PCR testing, the disclosure describes specific measures to capture demand, including expanding contract testing and sales of related reagents, in addition to continued demand. - FY2022-Q2First statedAnnual report
「As countries promoted COVID-19 vaccination, strong demand continued for ultra-low-temperature freezers needed to establish vaccine storage and distribution networks. We received numerous large orders from pharmaceutical companies, particularly in Europe and the United States, while demand for PCR testing in Japan also continued.」
The disclosure presents large orders for ultra-low-temperature freezers and PCR testing demand as opportunities to be captured through sales activities and expanded sales.